Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Early Detection of Mild Cognitive Impairment in Individual Patients

NCT00243451 · View on ClinicalTrials.gov ↗

Study Summary

Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of \[18\]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.

Interventions

  • OTHER PET scan & fMRI

Study Locations (1)

Louisiana

  • Louisiana State University Health Sciences Center — Shreveport

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2003-09
Est. Completion 2011-07

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00243451

The ClinicalTrials.gov registry entry for NCT00243451 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center Shreveport, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention — of which PET scan & fMRI is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00243451 reports 1 study location spanning 1 distinct geographic area — top geographies include Louisiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00243451 about?

NCT00243451 is a clinical study titled "Early Detection of Mild Cognitive Impairment in Individual Patients". Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of \[18\]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.

What is the current status of trial NCT00243451?

This trial is currently completed. The enrollment target is 34 participants. The study started on 2003-09. Estimated completion is 2011-07.

What conditions does trial NCT00243451 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Mild Alzheimer's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00243451?

The interventions under investigation include: PET scan & fMRI (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00243451?

This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00243451 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial